Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by NLM

MeSH
Adjuvants, Immunologic /administration & dosage /economics; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols /administration & dosage /economics; Costs and Cost Analysis; Cyclophosphamide /administration & dosage /economics; Doxorubicin /administration & dosage /analogs & derivatives /economics; Female; Granulocyte Colony-Stimulating Factor /administration & dosage /economics; Humans; Lymphoma, Non-Hodgkin /complications /drug therapy /economics; Male; Middle Aged; Neutropenia /drug therapy /economics /etiology; Prednisolone /administration & dosage /economics; Recombinant Proteins /administration & dosage /economics; Retrospective Studies; Vincristine /administration & dosage /economics

AccessionNumber
22007000883

Date bibliographic record published
15/05/2007